With a market capitalization (market cap) of $26.08B — a measure of how much the company is worth — Quest Diagnostics Incorporated is the 524th most valuable company in Healthcare as of August 18, 2026. Shares trade at $236.25, up +0.31% on the day.
of 2,587
price ÷ annual EPS
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Its core business involves the development and provision of diverse diagnostic information services, such as routine, advanced clinical, and anatomic pathology testing. While primarily operating under the Quest Diagnostics brand, it also leverages specialized identities like AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum to reach a broad spectrum of clients. Its extensive client base includes patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and other direct healthcare entities. Delivery of these services is facilitated through a robust network comprising laboratories, patient service centers, in-office phlebotomists, call centers, and mobile health professionals including paramedics and nurses. Additionally, the company provides risk assessment services for the life insurance industry and offers comprehensive information technology solutions to healthcare organizations and clinicians.
Visit websiteAs of August 18, 2026, Quest Diagnostics Incorporated (DGX) is worth $26.08B — this is its market capitalization, the total value of all its outstanding shares.
Quest Diagnostics Incorporated’s market cap is $26.08B, which ranks it #524 among the most valuable companies in the Healthcare sector tracked on MarketCapLens.
Quest Diagnostics Incorporated (DGX) shares trade at $236.25, up 0.31% on the day, as of August 18, 2026.
Fundamentals are annual. Figures labeled with their fiscal year.
FY 2025
Quest Diagnostics Incorporated trades at a price-to-earnings (P/E) ratio of 26.6, based on its latest share price and annual earnings per share.